Sun Yat-sen University

This study tests whether adding the immunotherapy drug Sintilimab to a standard chemotherapy regimen (P-GemOx) can safely and effectively treat people with newly diagnosed, advanced NK/T-cell lymphoma. The trial enrolled 34 adults aged 18-75 who had not received prior treatment. …

This study tests a combination of targeted radiation (SBRT), an immunotherapy drug (PD-1 antibody), and chemotherapy in 41 people with nasopharyngeal cancer that has spread to 5 or fewer spots in the body. The goal is to see if this approach can delay cancer growth and improve su…

This study tests whether adding an immunotherapy drug (PD-1 antibody) to standard chemotherapy can help people with a high-risk form of nasopharyngeal cancer that has come back. About 68 adults whose cancer returned at least a year after initial treatment and cannot be surgically…

This study tests whether eye pressure-lowering medication can slow the progression of severe nearsightedness (high myopia) in adults. Researchers will measure changes in eye length and vision over time. The trial includes 152 participants aged 18 to 65 with worsening high myopia …

This study tests whether adding the drug apatinib to standard chemotherapy and radiation can help people with advanced esophageal cancer that cannot be removed by surgery. About 170 participants will receive either the standard treatment or the standard treatment plus apatinib. T…

This study tests whether using smaller radiation targets after chemotherapy can still control cancer while reducing long-term side effects. It involves 445 adults with advanced nasopharyngeal cancer who have not been treated before. Researchers will compare relapse-free survival …

This study tests a treatment plan for muscle-invasive bladder cancer that aims to avoid removing the bladder. Participants first receive chemotherapy plus an immunotherapy drug (toripalimab), followed by radiation therapy with more immunotherapy. The goal is to see if this combin…

This study tests a new drug called AK112 in about 60 people with advanced kidney cancer that has spread. The drug works by helping the immune system fight cancer and cutting off the tumor's blood supply. Participants receive the drug every three weeks, and researchers will check …

This study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or come back and no longer responds to standard chemotherapy. The goal is to see if the combination can shrink tumors or slow cancer growth. Part…

This study tests whether using a smaller area of radiation on the neck is as effective as the standard larger area for people with nasopharyngeal cancer that hasn't spread. About 474 patients will be randomly assigned to receive either the reduced or conventional radiation. The g…

This study tests whether adding a liver-directed chemotherapy infusion to a two-drug immunotherapy regimen can help people with advanced liver cancer that has spread to the main vein of the liver. About 214 participants will be randomly assigned to receive either the triple thera…

This study tests a drug called surufatinib in people with advanced bone or soft tissue sarcoma whose cancer has not responded to standard chemotherapy. The goal is to see if the drug can slow or stop tumor growth. About 47 participants aged 14 to 70 will receive the drug and be m…

This study tests whether adding thymosin alpha 1 to standard treatment helps people with advanced lung cancer complete a full year of immunotherapy after chemoradiation. About 114 adults with non-small cell lung cancer that cannot be surgically removed will participate. The goal …

This study tests a combination of two drugs (toripalimab and bevacizumab) alongside three types of artery-directed treatments for people with liver cancer that cannot be removed by surgery. The goal is to see which artery treatment works best with the drug combo to control the ca…

This study tests a combination of three drugs (surufatinib, sintilimab, and AG) as the first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this mix shrinks tumors and delays cancer growth. The trial enrolled 32 adult…

This study is testing a treatment called photodynamic therapy (PDT) for people whose superficial esophageal cancer has come back or remained after prior treatments. Patients receive a light-sensitive drug called hematoporphyrin, then a laser activates it to destroy cancer cells. …

This study tests a combination of two drugs (zimberelimab and lenvatinib) in 30 people with advanced cervical cancer that got worse after prior immunotherapy. The goal is to see if the combo can shrink tumors and control the disease. Participants must have tried platinum-based ch…

This study tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy before and after main treatment can improve outcomes for people with advanced nasopharyngeal cancer. About 450 adults with stage III-IVA disease will receive either the drug combo or a pl…

This study tests a three-step treatment for elderly patients (ages 60-80) with a high-risk type of lymphoma called double-expressor DLBCL. First, patients receive a chemotherapy-free drug combination. Depending on how well the cancer responds, they then get standard chemotherapy …

This study tests a new drug called cadonilimab, combined with chemotherapy and radiation, for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if this combination can better control the cancer and prevent it from coming back. About 46 p…

This study tests whether giving a combination of three drugs (finotonlimab, cetuximab, and docetaxel) before surgery can shrink tumors in people whose head and neck cancer has come back after prior immunotherapy and chemotherapy. The goal is to see if this approach leads to fewer…

This study tests a combination of two drugs, ensartinib and bevacizumab, in people with a specific type of advanced lung cancer that has changes in the ALK and TP53 genes. The goal is to see if this combination can keep the cancer from growing for longer. The study includes 47 ad…

This study tests a new combination treatment for adults with liver cancer that no longer responds to standard targeted-immunotherapy. About 62 participants will receive QL1706 (a dual immune drug) along with either local chemotherapy or another targeted drug. The goal is to see i…

This study tests whether adding anlotinib hydrochloride to the standard Stupp regimen helps people with newly diagnosed glioblastoma live longer without their cancer growing. About 150 adults aged 18-75 are participating. The main goal is to see if the combination delays disease …

This study looks at whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. About 84 participants will take entecavir during and for 6…

This study tests a combination of three drugs (anlotinib, penpulimab, and capecitabine) as a first treatment for people whose nasopharyngeal cancer has spread or come back. About 59 adults aged 18-65 with measurable tumors will receive the therapy. The goal is to see how long the…

This study tests whether two drugs, Serplulimab and Fruquintinib, can prevent a rare kidney cancer (non-clear cell renal cell carcinoma) from returning after surgery. About 40 adults at high risk of recurrence will receive both drugs for up to 12 months. The goal is to see how lo…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This study tests whether adding the immunotherapy drug sintilimab to the chemotherapy drug capecitabine works better than capecitabine alone for people with advanced nasopharyngeal carcinoma who did not respond well to initial chemotherapy. About 150 adults aged 18-70 will receiv…

This study tests whether adding two immunotherapy drugs (ipromlimab and tuvonralimab) to standard chemotherapy before surgery can help shrink tumors in people with locally advanced esophageal cancer. About 62 participants will receive the combination treatment. The main goal is t…

This study looks at whether giving chemotherapy both before and after surgery (perioperative) is better than only after surgery for people with advanced colon cancer. About 738 participants will be randomly assigned to one of two groups. The goal is to see if the perioperative ap…

This study tests whether closing the pelvic floor peritoneum during laparoscopic rectal cancer surgery can prevent a common complication called ileus (bowel blockage). About 516 adults with mid-low rectal cancer will be randomly assigned to have the pelvic floor closed or left op…

This study tests if wearing tight gloves and foot caps during chemotherapy can prevent nerve damage caused by the drug paclitaxel. 182 people with nasopharyngeal cancer will wear the pressurized gear on one hand and foot, while the other side serves as a comparison. The goal is t…

This study looks at whether giving morphine into the spine (intrathecal) before laparoscopic colon cancer surgery helps patients feel better and recover faster. About 252 adults having this surgery will be invited to join. The goal is to see if this approach reduces pain, cuts do…

This study looks at how the heart works during a 6-minute walk test in people with advanced lung cancer who are getting chemotherapy, radiation, and immunotherapy. The goal is to see if heart measurements can help predict side effects and survival. About 231 adults with untreated…

This study tests a new way to grade carotid plaques using ultrasound, called Plaque-RADS, to see if it can predict stroke risk better than current methods. Researchers will collect data from 855 people with asymptomatic carotid plaques, both from past records and new patients. Th…

This study looks at how the bacteria in the gut (microbiome) are connected to cancer-related symptoms in children aged 5-18 with acute lymphoblastic leukemia. Researchers will collect stool samples and symptom reports at several points during chemotherapy. The goal is to understa…